Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Sunmo succeeds in a setting very similar to Starglo's.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
When your investment case breaks down, why not just do the decent thing?
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
